101620-10-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine is used as a pharmaceutical intermediate for the synthesis of various drugs and pharmaceutical compounds. Its role in this industry is crucial due to its potential to contribute to the development of new medications for treating a range of disorders.
Used in Research and Development:
In the field of research and development, 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine is utilized for studying its pharmacological properties, including its potential antipsychotic and anticonvulsant activities. This research is essential for understanding the compound's mechanism of action and exploring its potential clinical applications in the treatment of psychiatric and neurological disorders.

Upstream product

• 101620-09-1 N-{4-[4-(diphenylmethyl)piperazin-1-yl]butyl}isoindoline-1,3-dione 
• 841-77-0 diphenylmethylpiperazine 
• 628-20-6 4-Chlorobutyronitrile 

Downstream Products

• 124502-70-1 Quinoline-3-carboxylic acid [4-(4-benzhydryl-piperazin-1-yl)-butyl]-amide 
• 124502-64-3 N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxamide 
• 120301-45-3 N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(4-hydroxyphenyl)acrylamide 
• 120314-10-5 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-furan-2-yl-acrylamide 
• 120301-47-5 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(3-fluoro-phenyl)-acrylamide 
• 120301-42-0 N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(4-fluorophenyl)acrylamide 
• 120301-43-1 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(4-chloro-phenyl)-acrylamide 
• 123530-62-1 (E)-N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(2-pyrazinyl)acrylamide 
• 123530-70-1 (E)-N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(3-pyridazinyl)acrylamide 
• 123530-71-2 (E)-N-<(4-diphenylmethyl-1-piperazinyl)butyl>-3-(4-pyridazinyl)acrylamide 
• 118420-34-1 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(2-methyl-pyridin-3-yl)-acrylamide 
• 123530-73-4 (E)-N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(2-pyrrolyl)acrylamide 
• 107755-64-6 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-2-phenyl-3-pyridin-3-yl-acrylamide 
• 120301-53-3 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-naphthalen-2-yl-acrylamide 

Relevant academic research and scientific papers

Synthesis and histamine H1-receptor antagonist activity of 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment

New 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment were synthesized and evaluated for their antihistaminic anticholinergic and antiallergic activities. Tested compounds were found to be moderate to potent in vitro (guinea-pig ileum) histamine H1-receptor antagonists. Derivatives with a four methylene chain (1e-1h) were as potent in vivo (capillary permeability in rats) as cetirizine; the heteroaryl derivatives 1e and 1h were found to be the most active agents. These compounds displayed only weak in vitro (guinea-pig ileum) muscarinic M3-receptor antagonist activity. Compounds 1e and 1g were about 100 times more potent than ketotifen in preventing the compound 48/80-induced histamine release from rat peritoneal mast cells. Derivatives 1e, 1f and 1h did not modify the spontaneous motor activity in rats at 100 mg/kg po. Compound 1e has been selected for further studies.

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.

Synthesis, Structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds

We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the Structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine.

Hybrid approach for the design of highly affine and selective dopamine D3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands

A series of compounds containing privileged scaffolds of the known histamine H1 receptor antagonists cetirizine, mianserin, ketotifen, loratadine, and bamipine were synthesized for further optimization as ligands for the related biogenic amine binding dopamine D3 receptor. A pharmacological screening was carried out at dopamine D2 and D3 receptors. In the preliminary testing various ligands have shown moderate to high affinities for dopamine D3receptors, for example, N-(4-{4-[benzyl(phenyl)amino]piperidin-1-yl}butylnaphthalen-2-carboxamide (19a) (hD3 Ki = 0.3 nM; hD2 Ki = 703 nM), leading to a selectivity ratio of 2343.

THIAZOLIDINECARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR THERAPEUTIC USES

Thiazolidinecarboxylic acid amides having combined antiallergic and antiasthmatic activities with an antagonist activity against platelet Activating Factor and having the following general formula (I) STR1